vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
Prime Medicine, Inc. is the larger business by last-quarter revenue ($838.0K vs $421.0K, roughly 2.0× SenesTech, Inc.). SenesTech, Inc. runs the higher net margin — -428.5% vs -5498.7%, a 5070.2% gap on every dollar of revenue. On growth, SenesTech, Inc. posted the faster year-over-year revenue change (-16.0% vs -61.6%). SenesTech, Inc. produced more free cash flow last quarter ($-1.7M vs $-37.5M).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
PRME vs SNES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $421.0K |
| Net Profit | $-46.1M | $-1.8M |
| Gross Margin | — | 55.3% |
| Operating Margin | -5800.5% | -446.8% |
| Net Margin | -5498.7% | -428.5% |
| Revenue YoY | -61.6% | -16.0% |
| Net Profit YoY | -9.0% | -43.7% |
| EPS (diluted) | $-0.22 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | $421.0K | ||
| Q3 25 | $1.2M | $690.0K | ||
| Q2 25 | $1.1M | $625.0K | ||
| Q1 25 | $1.5M | $485.0K | ||
| Q4 24 | $2.2M | $501.0K | ||
| Q3 24 | — | $482.0K | ||
| Q2 24 | $0 | $459.0K | ||
| Q1 24 | $591.0K | $415.0K |
| Q4 25 | $-46.1M | $-1.8M | ||
| Q3 25 | $-50.6M | $-1.3M | ||
| Q2 25 | $-52.6M | $-1.6M | ||
| Q1 25 | $-51.9M | $-1.7M | ||
| Q4 24 | $-42.3M | $-1.3M | ||
| Q3 24 | — | $-1.5M | ||
| Q2 24 | $-55.3M | $-1.6M | ||
| Q1 24 | $-45.8M | $-1.8M |
| Q4 25 | — | 55.3% | ||
| Q3 25 | — | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 64.5% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | 65.4% | ||
| Q2 24 | — | 54.2% | ||
| Q1 24 | — | 32.5% |
| Q4 25 | -5800.5% | -446.8% | ||
| Q3 25 | -4406.0% | -195.2% | ||
| Q2 25 | -4787.2% | -258.2% | ||
| Q1 25 | -3603.3% | -342.9% | ||
| Q4 24 | -2025.7% | -250.9% | ||
| Q3 24 | — | -321.0% | ||
| Q2 24 | — | -349.0% | ||
| Q1 24 | -8179.5% | -444.1% |
| Q4 25 | -5498.7% | -428.5% | ||
| Q3 25 | -4129.1% | -188.1% | ||
| Q2 25 | -4716.7% | -258.6% | ||
| Q1 25 | -3568.8% | -343.3% | ||
| Q4 24 | -1936.6% | -250.5% | ||
| Q3 24 | — | -313.9% | ||
| Q2 24 | — | -345.1% | ||
| Q1 24 | -7743.0% | -441.4% |
| Q4 25 | $-0.22 | $0.48 | ||
| Q3 25 | $-0.32 | $-0.28 | ||
| Q2 25 | $-0.41 | $-0.87 | ||
| Q1 25 | $-0.40 | $-1.28 | ||
| Q4 24 | $-0.31 | $-0.15 | ||
| Q3 24 | — | $-2.07 | ||
| Q2 24 | $-0.46 | $-3.08 | ||
| Q1 24 | $-0.44 | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $9.6M |
| Total Assets | $342.7M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $8.6M | ||
| Q3 25 | $71.4M | $10.2M | ||
| Q2 25 | $53.8M | $6.1M | ||
| Q1 25 | $91.9M | $1.7M | ||
| Q4 24 | $182.5M | $1.3M | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | $55.6M | $2.0M | ||
| Q1 24 | $94.2M | $3.6M |
| Q4 25 | $120.9M | $9.6M | ||
| Q3 25 | $161.8M | $11.3M | ||
| Q2 25 | $60.9M | $7.0M | ||
| Q1 25 | $106.9M | $2.9M | ||
| Q4 24 | $153.1M | $2.5M | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | $196.6M | $3.1M | ||
| Q1 24 | $243.8M | $4.6M |
| Q4 25 | $342.7M | $12.8M | ||
| Q3 25 | $385.0M | $14.6M | ||
| Q2 25 | $279.0M | $10.4M | ||
| Q1 25 | $328.2M | $3.6M | ||
| Q4 24 | $297.5M | $3.3M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | $259.7M | $4.0M | ||
| Q1 24 | $311.4M | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-1.7M |
| Free Cash FlowOCF − Capex | $-37.5M | $-1.7M |
| FCF MarginFCF / Revenue | -4480.4% | -398.3% |
| Capex IntensityCapex / Revenue | 34.6% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | $-1.7M | ||
| Q3 25 | $-35.0M | $-1.4M | ||
| Q2 25 | $-41.4M | $-1.1M | ||
| Q1 25 | $-48.9M | $-1.6M | ||
| Q4 24 | $16.2M | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $-45.5M | $-1.6M | ||
| Q1 24 | $-67.7M | $-1.8M |
| Q4 25 | $-37.5M | $-1.7M | ||
| Q3 25 | $-35.3M | $-1.4M | ||
| Q2 25 | $-43.0M | $-1.2M | ||
| Q1 25 | $-51.3M | $-1.6M | ||
| Q4 24 | $14.5M | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $-47.4M | $-1.6M | ||
| Q1 24 | $-70.0M | $-1.8M |
| Q4 25 | -4480.4% | -398.3% | ||
| Q3 25 | -2880.5% | -205.9% | ||
| Q2 25 | -3855.1% | -191.5% | ||
| Q1 25 | -3526.8% | -328.5% | ||
| Q4 24 | 662.1% | -246.1% | ||
| Q3 24 | — | -296.1% | ||
| Q2 24 | — | -354.2% | ||
| Q1 24 | -11849.6% | -441.2% |
| Q4 25 | 34.6% | 3.1% | ||
| Q3 25 | 20.2% | 6.1% | ||
| Q2 25 | 141.0% | 7.5% | ||
| Q1 25 | 166.6% | 7.4% | ||
| Q4 24 | 82.0% | 3.0% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | 393.2% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
